Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Feb 16, 2017	Evoke Pharma Announces Pricing of Public Offering of Common Stock SOLANA BEACH, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that it has priced an underwritten public offering of 2,413,793 shares of its common stock at a price to	View HTML Evoke Pharma Announces Pricing of Public Offering of Common Stock 15.2 KB
Toggle Summary Feb 09, 2024	Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million SOLANA BEACH, Calif. , Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced today that it has priced an	View HTML PDF Version
Toggle Summary Jan 13, 2021	Evoke Pharma Announces Proposed Public Offering of Common Stock SOLANA BEACH, Calif. , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it intends to offer and sell shares of its common stock in a “firm commitment”	View HTML PDF Version
Toggle Summary Feb 15, 2017	Evoke Pharma Announces Proposed Public Offering of Common Stock SOLANA BEACH, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it intends to offer and sell shares of its common stock in a "firm commitment" underwritten	View HTML Evoke Pharma Announces Proposed Public Offering of Common Stock 15.4 KB
Toggle Summary Jun 24, 2015	Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis Second Phase 2 Trial Demonstrates Effectiveness of Intranasal Metoclopramide Spray	View HTML Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis 18.8 KB
Toggle Summary Mar 21, 2024	Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer SOLANA BEACH, Calif. , March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that Matthew J.	View HTML PDF Version
Toggle Summary Apr 28, 2014	Evoke Pharma Announces That EVK-001 Phase 2b Results Will be Presented at Digestive Disease Week 2014 SOLANA BEACH, Calif. , April 28, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from the Company's Phase 2b clinical trial of EVK-001, a novel intranasal formulation	View HTML Evoke Pharma Announces That EVK-001 Phase 2b Results Will be Presented at Digestive Disease Week 2014 16.3 KB
Toggle Summary Sep 09, 2014	Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001 SOLANA BEACH, Calif. , Sept. 9, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed enrollment in its thorough ECG (QT) study of EVK-001, the Company's lead	View HTML Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001 14.2 KB
Toggle Summary May 14, 2021	Evoke Pharma Appoints Vickie Reed to Board of Directors SOLANA BEACH, Calif. , May 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the appointment of Vickie Reed to the Company’s board of directors.	View HTML PDF Version
Toggle Summary Aug 08, 2016	Evoke Pharma Completes Credit Facility Repayment SOLANA BEACH, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced it has paid all of the outstanding amounts of indebtedness under its loan and	View HTML Evoke Pharma Completes Credit Facility Repayment 14.2 KB